Clicky

PTC Therapeutics, Inc.(PTCT)

Description: PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and proprietary small-molecule drugs for patients living with serious and life-threatening conditions, including genetic and neuromuscular disorders, cancer, and infectious diseases. Its approach includes post-transcriptional control, RNA biology, and gene expression modulation by small-molecules. The company has strategic alliances with AstraZeneca; Celgene Corporation; Cystic Fibrosis Foundation; Genzyme Corporation; Gilead; Muscular Dystrophy Association; Merck & Co., Inc.; Parent Project Muscular Dystrophy; Pfizer Inc.; Roche; Spinal Muscular Atrophy Foundation; and Wellcome Trust. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey.


Keywords: Biotechnology Cancer Biopharmaceutical Life Sciences Biology Infectious Diseases Neurological Disorders Gene Expression Dystrophy Cystic Fibrosis Muscular Dystrophy Transcription Neurodegenerative Disorders Spinal Muscular Atrophy Genzyme Neuromuscular Disorders

Home Page: www.ptcbio.com

PTCT Technical Analysis

100 Corporate Court
South Plainfield, NJ 07080
United States
Phone: 908 222 7000


Officers

Name Title
Dr. Stuart W. Peltz Ph.D. Co-Founder, CEO & Exec. Director
Dr. Allan Steven Jacobson Ph.D. Co-Founder, Chairman of Scientific Advisory Board & Independent Director
Ms. Emily Luisa Hill Chief Financial Officer
Dr. Neil Almstead Ph.D. Chief Technical Operations Officer
Mr. Mark Elliott Boulding Exec. VP & Chief Legal Officer
Mr. Eric Pauwels Chief Bus. Officer
Ms. Dawn A. Svoronos Advisor
Dr. Matthew B. Klein F.A.C.S., FACS, M.D., M.S., MS Chief Operating Officer
Ms. Christine Utter Sr. VP, Chief Accounting Officer & Head of People Services
Ms. Ellen Welch Ph.D. Chief Scientific Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1743.2734
Price-to-Sales TTM: 4.0332
IPO Date: 2013-06-20
Fiscal Year End: December
Full Time Employees: 1167
Back to stocks